Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
34.51
+6.66 (23.91%)
Mar 6, 2026, 2:40 PM EST - Market open
Tectonic Therapeutic Employees
Tectonic Therapeutic had 60 employees as of December 31, 2025. The number of employees increased by 9 or 17.65% compared to the previous year.
Employees
60
Change (1Y)
9
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,235,850
Market Cap
647.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 60 | 9 | 17.65% |
| Dec 31, 2024 | 51 | 7 | 15.91% |
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 265 |
| Allogene Therapeutics | 229 |
| Rocket Pharmaceuticals | 202 |
| Rigel Pharmaceuticals | 164 |
| Prothena Corporation | 163 |
| Neumora Therapeutics | 95 |
| Verastem | 78 |
| CorMedix | 65 |
TECX News
- 7 days ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 10 days ago - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - GlobeNewsWire
- 22 days ago - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 - GlobeNewsWire
- 3 months ago - Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point - Seeking Alpha
- 4 months ago - Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript - Seeking Alpha
- 4 months ago - Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewsWire
- 6 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire
- 8 months ago - Tectonic Therapeutic Joins Russell 3000® Index - GlobeNewsWire